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Urocortin protects chondrocytes from NO-induced
apoptosis: a future therapy for osteoarthritis?
NY Intekhab-Alam1, OB White1, SJ Getting2, A Petsa1, RA Knight3, HS Chowdrey1, PA Townsend4, KM Lawrence4 and IC Locke*,1
Osteoarthritis (OA) is characterized by a loss of joint mobility and pain resulting from progressive destruction and loss of
articular cartilage secondary to chondrocyte death and/ or senescence. Certain stimuli including nitric oxide (NO) and the pro-
inflammatory cytokine tumor necrosis factor a (TNF-a have been implicated in this chondrocyte death and the subsequent
accelerated damage to cartilage. In this study, we demonstrate that a corticotrophin releasing factor (CRF) family peptide,
urocortin (Ucn), is produced by a human chondrocyte cell line, C-20/A4, and acts both as an endogenous survival signal and as a
cytoprotective agent reducing the induction of apoptosis by NO but not TNF-a when added exogenously. Furthermore, treatment
with the NO donor S-nitroso-N-acetyl-D-L-penicillamine upregulates chondrocyte Ucn expression, whereas treatment with TNF-a
does not. The chondroprotective effects of Ucn are abolished by both specific ligand depletion (with an anti-Ucn antibody) and by
CRF receptor blockade with the pan-CRFR antagonist a-helical CRH(9-41). CRFR expression was confirmed by reverse
transcription-PCR with subsequent amplicon sequence analysis and demonstrates that C-20/A4 cells express both CRFR1 and
CRFR2, specifically CRFR1a and CRFR2b. Protein expression of these receptors was confirmed by western blotting.
The presence of both Ucn and its receptors in these cells, coupled with the induction of Ucn by NO, suggests the existence of an
endogenous autocrine/paracrine chondroprotective mechanism against stimuli inducing chondrocyte apoptosis via the
intrinsic/mitochondrial pathway.
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Articular cartilage of the joints forms a smooth, shock-
absorbing surface covering opposing subchondral bone and
is essential for the normal function of the joint.1 This
connective tissue is produced by only one type of specialized
cell, the chondrocyte. The extracellular matrix produced and
recycled by these cells is rich in collagen fibers embedded in
proteoglycans and provides high mechanical strength. These
cells are therefore crucial for normal joint integrity.2,3 During
the aging process and in pathologies of the aged, such as
osteoarthritis (OA), there is a loss of joint mobility and pain
especially in the knees, hips, hands and vertebrae. In OA,
these changes have been attributed to a reduction in the
number of active chondrocytes in articular cartilage, occurring
primarily in the superficial zone of the cartilage without distinct
changes in the middle or deep zones4 and the severity of
cartilage damage correlates very closely with the number of
remaining active cells.4,5 In these conditions, chondrocyte
death appears to be essentially apoptotic, but with subtle
differences, for example, membrane ‘blebbing’ is rarely seen.
This has led to the phrase ‘chondroptosis’ being suggested to
describe the unique form of apoptosis/programmed cell death
observed in these cells.6
Although it has now become established that chondrocyte
cell death contributes to progressive articular cartilage
damage and a loss of joint function, the stimuli involved are
unclear. Several locally occurring factors have, however,
been implicated including nitric oxide (NO),7 oxygen-free
radicals,7 tumor necrosis factor a (TNF-a),8 interleukin
1b (IL-1b)9 and Fas ligand.10 The effects of these stimuli on
chondrocytes have been shown to contribute to accelerated
damage of articular cartilage in vivo.3 Of these, NO and
the pro-inflammatory cytokines TNF-a and IL-1b are likely to
be significant contributors to the apparent changes in
chondrocyte function and viability observed during cartilage
degradation. NO, in particular, is present in significant
quantities within OA joints in vivo11 and elevated levels of
NO in the cartilage and synovial fluidmay be a result of excess
production in response to a variety of mechanical and
chemical stresses. These increased levels of NO may be a
result of the action of a neuronal NO synthetase-like enzyme,
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which has been detected in OA cartilage but not in normal
articular cartilage.12 NO may also mediate cartilage matrix
loss by upregulation ofmatrix metalloproteinases (MMP-9 and
MMP-3) causing further degradation of the cartilage matrix.13
It has also been shown in vitro that the addition of a NOS
inhibitor can reduce the level of observed apoptotic cell
death.14 Certain experimental models of OA in various
species also indicate a correlation between the level of NO
production and prevalence of apoptotic cells in cartilage
tissue.15 It is clear that imbalances in cartilage homeostasis
observed in both OA and the aging process need to be
redressed and that key to this is the protection of chondro-
cytes from apoptotic death.
Recently, the neuropeptide urocortin (Ucn) has been found
to be elevated in the synovial fluid of patients with rheumatoid
arthritis.16 It also reduces inflammation and bone erosion in a
mouse model of the disease.17 Beyond this, little is known of
the role of Ucn in the pathobiology of OA. This small peptide
and its paralogs UcnII (human stresscopin-related peptide)
and UcnIII (human stresscopin) are members of the cortico-
trophin releasing factor (CRF) family. These peptides have
been demonstrated to have pleiotrophic effects on numerous
cell systems including anti-apoptotic actions in heart18 and the
regulation of skeletal osteoclast differentiation and resorp-
tion,19 acting in an autocrine or paracrine manner.20 These
agonists bind to two classes of receptor CRF receptor 1
(CRFR1) and CRFR2 (which are expressed as multiple
isoforms due to alternate RNA splicing21). Signaling complex-
ity is increased further by receptor promiscuity, enabling the
activation of different G proteins by the same receptor
subtype.22 Studies have demonstrated that Ucn can bind to
both CRFR1 and CRFR2, whereas Ucn II and Ucn III bind
exclusively to CRFR2.23 The system is completed by a high-
affinity binding protein (CRF-BP), which acts as a decoy
receptor and regulates functional peptide availability.24
Here we report that Ucn is expressed in the chondrocyte cell
line C-20/A4, and that this cell line expresses both CRFR1
and R2 receptor subtypes. Furthermore, Ucn is essential for
C-20/A4 cell survival, and is also a potent chondroprotective
agent against cell death induced by pro-apoptotic stimuli.
Results
The effects of pro-apoptotic stimuli on C-20/A4
chondrocytes. C-20/A4 cell death was analyzed in the
presence of ascending concentrations of the pro-apoptotic
stimuli S-nitroso-N-acetyl-D-L-penicillamine (SNAP), a nitric
oxide (NO) donor and TNF-a. C-20/A4 cultures were
analyzed for apoptotic cell death by Annexin V and terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assays with the use of cytoplasmic lactate
dehydrogenase (LDH) release as a measure of necrosis.
The effects of SNAP treatment are shown in Figure 1a and
TNF-a treatment in Figure 1b.
SNAP treatment exhibited a dose-dependent increase in
apoptotic cell death with no significant increase in necrosis
(P40.05 versus control) at all concentrations tested. SNAP
(0.1mM) showed minimal apoptotic death (15% Annexin
V- and 8% TUNEL-positive cells) but as the dose of
SNAP increased, apoptotic levels increased with 23%
Annexin V- and 18% TUNEL-positive cells (Po0.01 versus
control) at 1mM and 35% Annexin V and 33% TUNEL-
positive cells (Po0.01 versus control) at 10mM. Based on
these data a concentration of 1mM SNAP was used for all
subsequent experiments.
TNF-a treatment similarly showed a dose-dependent
increase in apoptotic cell death, again with no significant
increase in necrosis (P40.05 versus control) at all concen-
trations tested. Minimal apoptotic cell death was apparent at
concentrations up to 40 pg/ml (P40.05 versus control)
but apoptotic cell death was observed at concentrations of
60 pg/ml and above with a significant (Po0.01 versus control)
increase to 24% Annexin V-positive cells. A small increase in
TUNEL-positive cells was evident, but this was not statistically
significant (P40.05 versus control). 80 pg/ml TNF-a treat-
ment resulted in a significant (Po0.001 versus control)
increase in both Annexin V and TUNEL positivity (29% and
33%, respectively). Based on these data a concentration of
70 pg/ml TNF-a was used for all subsequent experiments.
The endogenous expression of Ucn and its receptors by
C-20/A4 chondrocytes. Optimum annealing temperature
and amplification cycle number (linear part of the amplifica-
tion curve) were determined for reverse transcription-
PCR (RT-PCR) of Ucn and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) in C-20/A4 chondrocytes (full data
not shown, optimum conditions described in Table 1). Ucn
and GAPDH expression were analyzed by agarose gel
electrophoresis (Figure 2a) and quantified by densitometric
analysis of the resulting PCR amplicons with Ucn expression
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Figure 1 Apoptotic and necrotic chondrocyte cell death assessed as
the percentage of Annexin V- and TUNEL-positive cells (apoptosis) and cellular
LDH release (necrosis) following treatment of C-20/A4 cells with increasing
concentrations of SNAP (a) and TNF-a (b). *Po0.05. **Po0.01 compared with
control (untreated)
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‘normalized’ to GAPDH expression (Figure 2b). Basal
expression of Ucn and GAPDH was determined in control/
untreated cells and the ratio of Ucn/GAPDH expression
compared with that in cells treated with SNAP and TNF-a.
Figures 2a and b clearly indicate that SNAP treatment results
in an increased expression of Ucn (Po0.01 versus control),
whereas TNF-a treatment does not appreciably induce Ucn
expression (P40.05 versus control).
Again, following the identification of optimum annealing
temperatures and amplification cycle number for RT-PCR of
the CRF receptors in C-20/A4 chondrocytes (full data not
shown, optimum conditions described in Table 1), we have
identified the expression of both CRFR1 and CRFR2 receptor
subtypes in these cells. Specifically, we demonstrate
the expression of CRFR1a and CRFR2b subtypes, and the
identities of the PCR products were confirmed by direct
sequencing. Protein expression of both classes of receptor
was confirmed by western blotting with antibodies specific for
CRFR1 and CRFR2 (Figure 3).
Endogenous Ucn production is required for
chondrocyte survival. In order to assess the importance
of the endogenous, inducible Ucn expression demonstrated
above, we performed receptor blocking and ligand depletion
studies and determined the effects of these actions on
C-20/A4 chondrocyte death in the absence of pro-apoptotic
stimuli (Figure 4). Treatment with the non-selective CRFR
antagonist a-helical CRH(9-41) alone (10
 8M) resulted in a
significant (Po0.01 versus control) increase in apoptotic cell
Table 1 Sequences of primers used for PCR amplification of cDNA and predicted amplicon sizes
Gene Primer sequence (50-30) Expected product size (bp) PCR protocol Cycles
UCN CAGGCGAGCGGCCGCG 146 941C/571C/721C 33
(Human) CTTGCCCACCGAGTCGAAT
GAPDH CCTGCTTCACCACCTTCTTG 437 941C/581C/721C 30
(Human) CATCATCTCTGCCCCCTCTG
CRH-R1 ACAAACAATGGCTACCGGGA 280 (R1a) 941C/581C/721C 45
(Human) GGACCACGAACCAGGTGGCG 367 (R1b)
CRH-R2 AGCCCATTTTGGATGACAAG 180 941C/581C/721C 45
(Human) AGGTGGTGATGAGGTTCCAG
CRH-R2a TCCACAGCCTGCTGGAGGCC 239 941C/581C/721C 45
(Human) CTCCAAGCATTCTCGATAGGC
CRH-R2b CCTCCTCTACGTCCCACACC 310 941C/581C/721C 45
(Human) CTCCAAGCATTCTCGATAGGC
CRH-R2g TGGGAAGAGAGCCTTGGCC 212 941C/581C/721C 45
(Human) CTCCAAGCATTCTCGATAGGC
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Figure 2 (a) RT-PCR analysis of Ucn (upper panel) and GAPDH (lower panel) expression in control (untreated) C-20/A4 chondrocytes and cells treated with 1 mM SNAP
and 70 pg/ml TNF-a. Ucn and GAPDH amplicon sizes are indicated. (b) Ratio of Ucn/GAPDH expression in control (untreated) C-20/A4 chondrocytes and cells treated with
1 mM SNAP and 70 pg/ml TNF-a as determined by densitometric analysis of PCR products shown in a. (c) RT-PCR analysis of CRFR subtype expression in C-20/A4
chondrocytes. Lanes 1 and 2¼CRFR1 product, lane 3¼CRFR1-negative control, lanes 5 and 6¼CRFR2 product, lane 7¼CRFR2-negative control. CRFR amplicon sizes
are indicated. (d) RT-PCR analysis of CRFR2 splice variant expression in C-20/A4 chondrocytes. Lanes 1 and 2¼CRFR2a PCR – no product, lane 3¼CRFR2a-negative
control, lanes 5 and 6¼CRFR2b PCR product, lane 7¼CRFR2b-negative control, lanes 9 and 10¼CRFR2g PCR – no product, lane 11¼CRFR2g-negative control.
CRFRb amplicon size is indicated
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Figure 3 (a) Western-blot analysis of CRFR expression. CRFR1 and CRFR2
protein levels were determined using rabbit anti-CRFR1 and rabbit anti-CRFR2
monoclonal antibodies with a mouse anti-a-tubulin monoclonal antibody used as a
loading control. Bands with sizes corresponding to 50 kDa (CRFR1), 47 kDa
(CRFR2) and 55 kDa (a-tubulin) were detected. (b) Observed bands were quantified
by densitometry and CRFR expression normalized to that of a-tubulin. Data are
presented as mean±S.E.M. of three independent experiments
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death (23% Annexin V, 23% TUNEL) with no significant
increase in necrotic cell death as determined by LDH
release. Ligand depletion studies with a specific anti-human
Ucn antibody resulted in even greater increases in apoptotic
cell death (37% Annexin V, 33% TUNEL; Po0.01 versus
control), whereas treatment with an isotype control antibody
directed against human albumin resulted in no significant
increase in apoptosis as compared with the control. There
was no significant increase in necrotic cell death following
treatment with either antibody.
The addition of exogenous Ucn is chondroprotective
against pro-apoptotic stimuli. Using the optimum concen-
trations of SNAP (1mM) and TNF-a (70 pg/ml) as determined
in Figure 1, C-20/A4 chondrocytes were treated with these
stimuli, in conjunction with the addition of exogenous
Ucn (10 8M). Figure 5 demonstrates that the addition of
concomitant Ucn ameliorates the apoptotic cell death
induced by both SNAP and TNF-a but appears more effective
against that induced by SNAP. Treatment with both Ucn and
SNAP resulted in a significant reduction of apoptosis
(14% Annexin V and 10% TUNEL) when compared with
SNAP alone (23% Annexin V and 19% TUNEL; Po0.01).
Treatment with Ucn and TNF-a resulted in a significant
reduction in TUNEL positivity when compared with TNF-a
alone (from 19% to 12%, Po0.05) but no significant
reduction in Annexin V-positive cells. In both the cases, the
chondroprotective effect of Ucn is blocked by the addition of
a-helical CRH(9-41) resulting in levels of cell death that are not
significantly different to treatment with the pro-apoptotic
stimuli alone.
Discussion
Given that chondrocyte apoptosis or ‘chondroptosis’ is thought
to be one of themajormechanisms involved in the pathogenesis
of OA, and that we have previously shown Ucn to be cytopro-
tective in cardiacmyocytes25 and neuronal cells,26 we sought to
investigate a potential role for this peptide in chondrocyte
responses to pro-apoptotic stimuli implicated in OA.
NO and the pro-inflammatory cytokine TNF-a have both
been detected at elevated levels in osteoarthritic cartilage and
both been implicated as possible contributors to chondrocyte
death and cartilage damage.11,8 TNF-a is also involved in the
amplification of the local inflammatory response within the
joint.27 Initial data gathered in this study (Figures 1a and b)
confirm a dose-dependent increase in apoptotic cell death
following treatment of C-20/A4 cells with these stimuli as
determined by both Annexin V binding and TUNEL assays.
No significant increase in necrotic cell death (as determined
by cytoplasmic LDH release) was noted at all concentrations
tested. Concentrations of 1mM SNAP (which releases
approximately 60 nM of free NO28) and 70 pg/ml TNF-a were
selected for all further studies as these concentrations
induced a consistent and easily quantifiable level of chon-
drocyte apoptosis with minimal necrosis. Furthermore, these
concentrations are similar to those found within OA joints and
similar to those used by others in studies with primary human
chondrocytes.11,29,30
In order to establish the potential of the Ucn system as a
chondroprotective mechanism, expression of Ucn and CRFR
mRNA in C-20/A4 cells was first investigated in untreated,
control cells where RT-PCR demonstrated constitutive
expression of both Ucn and CRFRs (Figure 2a, lane 1 and
Figure 2c, respectively) with the identity of the resulting
amplicons confirmed by sequence analysis. Not only is the
demonstration of Ucn expression in chondrocytes novel,
these studies and the accompanying western blotting studies
(Figure 3) also intriguingly demonstrated the expression of
both CRFR1 and CRFR2 receptor subtypes in these cells
(CRFR1a and CRFR2b), a phenomenon that, as far as we are
aware, has not previously been reported. The identity of these
receptor subtype variants further confirms that both subtypes
are represented by an active splice-variant with CRFR1a
being the only active CRFR1 isoform31 and CRFR2b being
one of the three active forms of CRFR2 (CRFR2a, CRFR2b
and CRFR2g).32 Furthermore, although CRFR2a is the
predominant CRFR2 isoform expressed in the human
periphery, it has been shown through adenylate cyclase
activation studies that Ucn and the other CRF-related
peptides may preferentially activate the larger CRFR2b
isoform over CRFR2a and CRFR2g,33 despite there being
no pharmacological differences in ligand binding.32 This may
be explained by the fact that the CRFR2a and CRFR2g
isoforms lack the N-terminal domain encoded by exons 1 and
2 of the CRFR2 gene, an extracellular region thought
to be important in ligand recognition and interaction.33 Having
confirmed the expression of both Ucn and its receptors, we
then studied the effects of pro-apoptotic insults on cellular
expression of these components of the Ucn system. Although
there was no significant variation in receptor expression
following treatment with pro-apoptotic stimuli (data not
shown), ligand expression was, however, significantly
induced by SNAP, but not TNF-a treatment (Figure 2a, lanes
3 and 5, respectively, and Figure 2b). Following normalization
of the PCR data by expressing the data as a ratio of Ucn/
GAPDH densitometry readings, it becomes readily apparent
that Ucn expression increases nearly twofold following
exposure to SNAP (Po0.01 versus control) yet there is no
significant change following TNF-a exposure (Figure 2b).
These data would suggest that the Ucn system is
therefore likely to represent a constitutive chondroprotective
mechanism but moreover that it may represent a mechanism
specifically targeted toward protection against certain stimuli.
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Figure 4 Cytoprotective effects of endogenous Ucn. Apoptotic and necrotic
chondrocyte cell death assessed as the percentage of Annexin V- and TUNEL-
positive cells (apoptosis) and cellular LDH release (necrosis) following the treatment
of C-20/A4 cells, with the CRH receptor antagonist a-helical CRH, anti-UCN
antibody and anti-albumin antibody, **Po0.01 compared with control
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Following the demonstration of Ucn mRNA production by
C-20/A4 cells the presence of functional endogenous
Ucn production was confirmed by CRFR receptor blockade
(by a-helical CRH(9-41), a competitive inhibitor of both CRFR1
and CRFR2 receptor subclasses) and the specific depletion
of Ucn ligand released into the culture medium (using an
Ucn-specific antibody). These experiments not only demon-
strate the presence of functional Ucn peptide in these cells,
but also suggest that the Ucn system represents an essential
endogenous mediator of chondrocyte survival as both CRFR
blockade and selective ligand depletion result in high levels of
chondrocyte death, even in the absence of pro-apoptotic
stimuli. The addition of isotype control antibody (anti-human
albumin) did not result in any significant increase in
chondrocyte apoptosis when compared with control cells
(Figure 4).
In order to further characterize Ucn-mediated chondropro-
tection, and its possible selective nature, cytoprotection
experiments were performed with the addition of exogenous
Ucn, concomitant with SNAP and TNF-a treatment. As shown
in Figure 5, co-treatment with SNAP and exogenous Ucn
results in a significant decrease in the level of C-20/A4
apoptosis induced by SNAP treatment alone, protection that is
again reversed by the addition of a-helical CRH(9-41). When
added in conjunction with TNF-a, however, the chondropro-
tective effects of Ucn are much less evident. The TUNEL
assay data reveal a small reduction in cell death but the
Annexin V assay, however, does not show any significant
difference when compared with TNF-a treatment alone.
Taken together, these data would suggest that Ucn appears
to principally confer cytoprotection against pro-apototic stimuli
that induce cell death via the intrinsic/mitochondrial apoptotic
pathway (e.g., NO), but is less effective against stimuli acting
through the extrinsic/death receptor-mediated pathway
(e.g., TNF-a). These findings are in agreement with cardiac
myocyte-derived data where Ucn was shown to prevent
mitochondrial damage and inhibit lipid peroxidation resulting
from oxidative stress.34–36
Using a stable, well-established chondrocyte cell line, this
study has demonstrated critical roles for Ucn as both an
essential chondrocyte survival signal and as a chondropro-
tective agent in the presence of pro-apoptotic stimuli. As with
all studies involving cell lines, these observations should, and
will be, confirmed in primary chondrocytes but these two
characteristics ultimately represent a putative role for the Ucn
system in preserving cartilage tissue. Furthermore, when
coupled with our recently published data demonstrating a
potent anti-resorbtive role for Ucn in osteoclasts,19 a wider
role in bone metabolism and maintenance is suggested.
Together, these data would suggest that Ucn, by preserving
the ability to lay down new cartilage as well as reducing bone
resorption, may have therapeutic potential in both osteo-
porosis and OA.
Materials and Methods
Cell culture. In vitro experiments were performed with the C-20/A4 human
chondrocyte cell line37 cultured in a medium consisting of Dulbecco’s modified
Eagle’s medium containing 1 g/l glucose (Lonza, Wokingham, UK), supplemented
with 10% (v/v) fetal calf serum (FCS; Labtech International, Uckfield, UK), 1% (v/v)
L-glutamine and 1% (v/v) penicillin/streptomycin (Lonza) at 37 1C, 5% CO2. When
confluent, cells were passaged by treatment with Ca2þ and Mg2þ -free
phosphate-buffered saline (Lonza), prewarmed to 37 1C and used as required.
Following passage, the chondrocyte cell suspension (1 106 cells/ml) was
transferred to six-well tissue culture plates and incubated for 24–48 h in the above
medium to allow cells to reach B80% confluency. The cells were then ‘serum
starved’ for 24 h by replacing the normal, 10% FCS growth medium with medium
containing 1% FCS (all other components unchanged). The cultured cells were
then re-supplied with fresh 1% FCS medium (control) or treated with fresh 1%
medium containing the stimuli/reagents detailed below for 6 h, after which levels of
cell death were determined.
Six-well plate cultures were treated with individual or combination treatments of:
the NO donor SNAP (Calbiochem, Nottingham, UK), TNF-a (R&D Systems,
Abingdon, UK), the CRH antagonist a helical CRH(9-41) (10
 8 M; Sigma-Aldrich,
Gillingham, UK), rabbit anti-human Ucn antibody (100 mg/ml) and an isotype control
(anti-human albumin; 100mg/ml; both Sigma-Aldrich) and the level of chondrocyte
cell death compared.
Measurement of cell death. Control and treated C-20/A4 cultures were
assessed for both apoptotic and necrotic cell death. Apoptosis was assessed by
fluorescence microscopy by Annexin V binding (TACS Annexin V-FITC kit, R&D
systems) and by terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL; in situ cell death detection kit, Roche diagnostics, Lewes, UK).
Necrotic cell death was assessed by cytoplasmic LDH release (TOX 7 In Vitro
Toxicology assay kit, Sigma, Poole, UK). All assays were performed according to
the manufacturer’s standard protocol.
RNA isolation and RT-PCR. Total RNA was isolated using Qiagen RNeasy
Plus micro kit with gDNA eliminator columns to prevent genomic DNA
contamination (Qiagen, Crawley, UK) according to the manufacturer’s standard
protocol. RNA purity and concentration were determined spectrophotometrically at
260 and 280 nm in an Eppendorf Biophotometer (Eppendorf, Cambridge UK) and
RNA integrity verified by 1% agarose gel electrophoresis in tris(hydroxymethy-
l)aminomethane (Tris)-acetate-EDTA buffer followed by ethidium bromide
(200 ng/ml) staining and visualization on a UV transilluminator.
cDNA was synthesized from 2mg of each RNA sample using the Omniscipt
reverse transcriptase kit in the presence of an RNAse inhibitor, oligo dt primer and
mixed dNTPs (all from Qiagen). RNA and oligo dt mixes were initially heated to
70 1C for 10 min (to denature secondary RNA structures) after which the other
components were added and the final mix incubated at 37 1C for 1 h.
PCR was performed to assess the expression of Ucn system components (Ucn,
CRF-BP and CRFR) in C-20/A4 chondrocyte cells, using Qiagen Taq PCR Master
Mix (Qiagen). The target sequences were amplified using sequence-specific
oligonucleotide primers designed to amplify the transcript of interest along with
GAPDH as an internal reference. Primer sequences and PCR conditions are given
in Table 1. Temperature gradient PCR was performed on an Eppendorf
Mastercycler gradient PCR machine (Eppendorf, Cambridge, UK) to determine
optimum annealing temperatures for each of the primer pairs and the same machine
used for all subsequent amplifications. Products were visualized on 2% (w/v)
agarose gel electrophoresis in Tris-acetate-EDTA buffer followed by ethidium
bromide (200 ng/ml) staining and visualization on a UV transilluminator.
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Figure 5 Cytoprotective effects of exogenous Ucn. Apoptotic and necrotic
chondrocyte cell death assessed as the percentage of Annexin V- and TUNEL-
positive cells (apoptosis) and cellular LDH release (necrosis) following treatment of
C-20/A4 cells with Ucn (U) administered concurrently with SNAP (S) or TNF-a (T) in
the presence or absence of a-helical CRH (A) *Po0.05, **Po0.01 compared with
control (C).
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Where appropriate, densitometric analysis was employed to qualify gene
expression relevant to the GAPDH housekeeping gene. Amplicon identity was
confirmed by sequence analysis performed by GACT Biotech Ltd. (London, UK).
Western blotting. C-20/A4 expression of CRFR1 and CRFR2 receptors
was determined by western blotting as previously described.38,39 Following
electrophoresis in a 10% SDS-polyacrylamide gel, proteins were transferred onto
nylon membrane by electroblotting, blocked for 1 h in 5% non-fat milk solution in
Tris-hydrochloric acid-buffered saline, pH 7.5 (TBS) containing 0.1% (v/v)
Tween-20 and then incubated with either specific anti-CRFR1 or anti-CRFR2
(1 : 1000 dilution SAB4500465 and SAB4500466, Sigma-Aldrich, Dorset, UK)
rabbit antibodies in blocking solution. Blots were washed in TBS before the
addition of a secondary goat anti-rabbit HRP-conjugated antibody (1 : 2000
dilution) and specific antibody binding was detected by enhanced chemilumines-
cence (Pierce Biotechnology, Rockford, IL, USA). Following detection, bound
antibodies were removed by incubating the membranes in 100 mM glycine-
hydrochloric acid, pH 2.5, for 30 min and the blot re-probed to detect a-tubulin as
described previously.38,39 Densitometry analysis was performed using Image J
software (NIH, Bethesda, MD, USA).
Statistical analysis. Data values from the figures are expressed as
mean±S.D. of n-independent experiments. All experiments were repeated at
least nine times with the exception of the western blots, which were repeated three
times. All data were subjected to ANOVA followed by Bonferroni’s correction for
post hoc t-tests where appropriate. Probabilities of Pr0.05 were considered
statistically significant. Statistical tests were performed using Microsoft Excel or
Prism GraphPad software as applicable.
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